HALO Annual D&A
$84.86 M
+$35.22 M+70.94%
31 December 2023
Summary:
As of January 22, 2025, HALO annual depreciation & amortization is $84.86 million, with the most recent change of +$35.22 million (+70.94%) on December 31, 2023. During the last 3 years, it has risen by +$81.57 million (+2483.92%). HALO annual D&A is now at all-time high.HALO Depreciation And Amortization Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HALO Quarterly D&A
$20.36 M
+$29.00 K+0.14%
30 September 2024
Summary:
As of January 22, 2025, HALO quarterly depreciation & amortization is $20.36 million, with the most recent change of +$29.00 thousand (+0.14%) on September 30, 2024. Over the past year, it has dropped by -$2.72 million (-11.78%). HALO quarterly D&A is now -30.28% below its all-time high of $29.20 million, reached on September 30, 2022.HALO Quarterly D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HALO TTM D&A
$81.59 M
-$2.72 M-3.22%
30 September 2024
Summary:
As of January 22, 2025, HALO TTM depreciation & amortization is $81.59 million, with the most recent change of -$2.72 million (-3.22%) on September 30, 2024. Over the past year, it has increased by +$10.31 million (+14.47%). HALO TTM D&A is now -3.85% below its all-time high of $84.86 million, reached on December 31, 2023.HALO TTM D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HALO Depreciation And Amortization Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +70.9% | -11.8% | +14.5% |
| 3 y3 years | +2483.9% | -11.8% | +14.5% |
| 5 y5 years | +3453.4% | -11.8% | +14.5% |
HALO Depreciation And Amortization High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +2731.4% | -30.3% | +2533.9% | -3.9% | +2622.4% |
| 5 y | 5-year | at high | +2731.4% | -30.3% | +2670.1% | -3.9% | +2622.4% |
| alltime | all time | at high | >+9999.0% | -30.3% | >+9999.0% | -3.9% | >+9999.0% |
Halozyme Therapeutics Depreciation And Amortization History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $20.36 M(+0.1%) | $81.59 M(-3.2%) |
| June 2024 | - | $20.33 M(+0.6%) | $84.31 M(-0.4%) |
| Mar 2024 | - | $20.21 M(-2.4%) | $84.61 M(-0.3%) |
| Dec 2023 | $84.86 M(+70.9%) | $20.69 M(-10.3%) | $84.86 M(+19.1%) |
| Sept 2023 | - | $23.08 M(+11.9%) | $71.28 M(-7.9%) |
| June 2023 | - | $20.63 M(+0.8%) | $77.40 M(+11.7%) |
| Mar 2023 | - | $20.46 M(+187.6%) | $69.32 M(+39.6%) |
| Dec 2022 | $49.64 M(+1556.4%) | $7.11 M(-75.6%) | $49.64 M(+14.6%) |
| Sept 2022 | - | $29.20 M(+132.8%) | $43.30 M(+191.6%) |
| June 2022 | - | $12.55 M(+1512.6%) | $14.85 M(+388.9%) |
| Mar 2022 | - | $778.00 K(+0.6%) | $3.04 M(+1.3%) |
| Dec 2021 | $3.00 M(-8.7%) | $773.00 K(+2.9%) | $3.00 M(-0.9%) |
| Sept 2021 | - | $751.00 K(+2.2%) | $3.02 M(-1.7%) |
| June 2021 | - | $735.00 K(-0.4%) | $3.08 M(-2.8%) |
| Mar 2021 | - | $738.00 K(-7.8%) | $3.17 M(-3.6%) |
| Dec 2020 | $3.28 M(-19.3%) | $800.00 K(-0.4%) | $3.28 M(-6.9%) |
| Sept 2020 | - | $803.00 K(-2.5%) | $3.53 M(-5.3%) |
| June 2020 | - | $824.00 K(-3.9%) | $3.73 M(-5.3%) |
| Mar 2020 | - | $857.00 K(-17.8%) | $3.94 M(-3.3%) |
| Dec 2019 | $4.07 M(+70.4%) | $1.04 M(+4.0%) | $4.07 M(+12.5%) |
| Sept 2019 | - | $1.00 M(-3.1%) | $3.62 M(+12.1%) |
| June 2019 | - | $1.03 M(+4.4%) | $3.23 M(+14.7%) |
| Mar 2019 | - | $990.00 K(+67.8%) | $2.81 M(+17.8%) |
| Dec 2018 | $2.39 M(+10.5%) | $590.00 K(-3.6%) | $2.39 M(+4.2%) |
| Sept 2018 | - | $612.00 K(-1.3%) | $2.29 M(+5.3%) |
| June 2018 | - | $620.00 K(+9.5%) | $2.17 M(+2.4%) |
| Mar 2018 | - | $566.00 K(+14.8%) | $2.13 M(-1.7%) |
| Dec 2017 | $2.16 M(-10.3%) | $493.00 K(-0.6%) | $2.16 M(-6.5%) |
| Sept 2017 | - | $496.00 K(-13.0%) | $2.31 M(-6.4%) |
| June 2017 | - | $570.00 K(-5.3%) | $2.47 M(-2.1%) |
| Mar 2017 | - | $602.00 K(-6.5%) | $2.52 M(+4.7%) |
| Dec 2016 | $2.41 M(+43.7%) | $644.00 K(-1.5%) | $2.41 M(+8.3%) |
| Sept 2016 | - | $654.00 K(+5.0%) | $2.23 M(+12.8%) |
| June 2016 | - | $623.00 K(+27.4%) | $1.97 M(+13.1%) |
| Mar 2016 | - | $489.00 K(+6.5%) | $1.75 M(+4.1%) |
| Dec 2015 | $1.68 M(-4.8%) | $459.00 K(+14.2%) | $1.68 M(+0.1%) |
| Sept 2015 | - | $402.00 K(+1.8%) | $1.68 M(-3.6%) |
| June 2015 | - | $395.00 K(-6.2%) | $1.74 M(-2.7%) |
| Mar 2015 | - | $421.00 K(-8.1%) | $1.79 M(+1.4%) |
| Dec 2014 | $1.76 M(+43.6%) | $458.00 K(-1.3%) | $1.76 M(+7.6%) |
| Sept 2014 | - | $464.00 K(+4.7%) | $1.64 M(+11.1%) |
| June 2014 | - | $443.00 K(+11.6%) | $1.48 M(+11.0%) |
| Mar 2014 | - | $397.00 K(+18.9%) | $1.33 M(+8.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2013 | $1.23 M(+13.7%) | $334.00 K(+11.0%) | $1.23 M(+4.4%) |
| Sept 2013 | - | $301.00 K(+1.3%) | $1.18 M(+1.3%) |
| June 2013 | - | $297.00 K(+0.7%) | $1.16 M(+2.2%) |
| Mar 2013 | - | $295.00 K(+4.3%) | $1.14 M(+5.3%) |
| Dec 2012 | $1.08 M(-1.5%) | $282.80 K(-1.2%) | $1.08 M(+3.7%) |
| Sept 2012 | - | $286.20 K(+5.1%) | $1.04 M(+4.8%) |
| June 2012 | - | $272.20 K(+14.5%) | $992.90 K(-1.4%) |
| Mar 2012 | - | $237.80 K(-2.6%) | $1.01 M(-8.1%) |
| Dec 2011 | $1.10 M(-27.3%) | $244.20 K(+2.3%) | $1.10 M(-8.3%) |
| Sept 2011 | - | $238.70 K(-16.8%) | $1.20 M(-9.5%) |
| June 2011 | - | $286.80 K(-12.1%) | $1.32 M(-7.2%) |
| Mar 2011 | - | $326.20 K(-5.1%) | $1.42 M(-5.6%) |
| Dec 2010 | $1.51 M(+4.4%) | $343.80 K(-5.7%) | $1.51 M(-3.3%) |
| Sept 2010 | - | $364.50 K(-6.4%) | $1.56 M(-0.3%) |
| June 2010 | - | $389.40 K(-5.1%) | $1.56 M(+2.5%) |
| Mar 2010 | - | $410.30 K(+3.8%) | $1.53 M(+5.7%) |
| Dec 2009 | $1.44 M(+37.8%) | $395.20 K(+7.2%) | $1.44 M(+7.8%) |
| Sept 2009 | - | $368.50 K(+4.9%) | $1.34 M(+7.0%) |
| June 2009 | - | $351.40 K(+6.9%) | $1.25 M(+9.0%) |
| Mar 2009 | - | $328.60 K(+13.0%) | $1.15 M(+9.6%) |
| Dec 2008 | $1.05 M(+81.8%) | $290.80 K(+3.7%) | $1.05 M(+8.0%) |
| Sept 2008 | - | $280.50 K(+12.9%) | $970.60 K(+15.1%) |
| June 2008 | - | $248.40 K(+8.9%) | $843.30 K(+17.5%) |
| Mar 2008 | - | $228.20 K(+6.9%) | $718.00 K(+24.6%) |
| Dec 2007 | $576.50 K(+136.3%) | $213.50 K(+39.4%) | $576.40 K(+32.7%) |
| Sept 2007 | - | $153.20 K(+24.5%) | $434.20 K(+26.2%) |
| June 2007 | - | $123.10 K(+42.1%) | $344.10 K(+23.9%) |
| Mar 2007 | - | $86.60 K(+21.5%) | $277.70 K(+13.8%) |
| Dec 2006 | $244.00 K(+18.3%) | $71.30 K(+13.0%) | $244.10 K(+8.9%) |
| Sept 2006 | - | $63.10 K(+11.3%) | $224.10 K(+9.4%) |
| June 2006 | - | $56.70 K(+7.0%) | $204.90 K(-2.1%) |
| Mar 2006 | - | $53.00 K(+3.3%) | $209.20 K(+1.4%) |
| Dec 2005 | $206.30 K(+67.2%) | $51.30 K(+16.9%) | $206.30 K(+6.2%) |
| Sept 2005 | - | $43.90 K(-28.0%) | $194.30 K(+6.2%) |
| June 2005 | - | $61.00 K(+21.8%) | $183.00 K(+20.5%) |
| Mar 2005 | - | $50.10 K(+27.5%) | $151.90 K(+23.2%) |
| Dec 2004 | $123.40 K | $39.30 K(+20.6%) | $123.30 K(+329.6%) |
| Sept 2004 | - | $32.60 K(+9.0%) | $28.70 K(+71.9%) |
| June 2004 | - | $29.90 K(+39.1%) | $16.70 K(+271.1%) |
| Mar 2004 | - | $21.50 K(-138.9%) | $4500.00(+4400.0%) |
| Dec 2003 | - | -$55.30 K(-368.4%) | $100.00(-99.8%) |
| Sept 2003 | - | $20.60 K(+16.4%) | $55.40 K(+59.2%) |
| June 2003 | - | $17.70 K(+3.5%) | $34.80 K(+103.5%) |
| Mar 2003 | - | $17.10 K | $17.10 K |
FAQ
- What is Halozyme Therapeutics annual depreciation & amortization?
- What is the all time high annual D&A for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual D&A year-on-year change?
- What is Halozyme Therapeutics quarterly depreciation & amortization?
- What is the all time high quarterly D&A for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly D&A year-on-year change?
- What is Halozyme Therapeutics TTM depreciation & amortization?
- What is the all time high TTM D&A for Halozyme Therapeutics?
- What is Halozyme Therapeutics TTM D&A year-on-year change?
What is Halozyme Therapeutics annual depreciation & amortization?
The current annual D&A of HALO is $84.86 M
What is the all time high annual D&A for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual depreciation & amortization is $84.86 M
What is Halozyme Therapeutics annual D&A year-on-year change?
Over the past year, HALO annual depreciation & amortization has changed by +$35.22 M (+70.94%)
What is Halozyme Therapeutics quarterly depreciation & amortization?
The current quarterly D&A of HALO is $20.36 M
What is the all time high quarterly D&A for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly depreciation & amortization is $29.20 M
What is Halozyme Therapeutics quarterly D&A year-on-year change?
Over the past year, HALO quarterly depreciation & amortization has changed by -$2.72 M (-11.78%)
What is Halozyme Therapeutics TTM depreciation & amortization?
The current TTM D&A of HALO is $81.59 M
What is the all time high TTM D&A for Halozyme Therapeutics?
Halozyme Therapeutics all-time high TTM depreciation & amortization is $84.86 M
What is Halozyme Therapeutics TTM D&A year-on-year change?
Over the past year, HALO TTM depreciation & amortization has changed by +$10.31 M (+14.47%)